The ER membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane proteins
Abstract
The endoplasmic reticulum (ER) supports biosynthesis of proteins with diverse transmembrane domain (TMD) lengths and hydrophobicity. Features in transmembrane domains such as charged residues in ion channels are often functionally important, but could pose a challenge during cotranslational membrane insertion and folding. Our systematic proteomic approaches in both yeast and human cells revealed that the ER membrane protein complex (EMC) binds to and promotes the biogenesis of a range of multipass transmembrane proteins, with a particular enrichment for transporters. Proximity-specific ribosome profiling demonstrates that the EMC engages clients cotranslationally and immediately following clusters of TMDs enriched for charged residues. The EMC can remain associated after completion of translation, which both protects clients from premature degradation and allows recruitment of substrate-specific and general chaperones. Thus, the EMC broadly enables the biogenesis of multipass transmembrane proteins containing destabilizing features, thereby mitigating the trade-off between function and stability.
Data availability
Sequencing data have been deposited in GEO under accession code GSE112891.
-
The ER membrane protein complex interacts cotranslationally to enable biogenesis of multipass membrane proteinsPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE112891).
-
The SND proteins constitute an alternative targeting route to the endoplasmic reticulumPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE85686).
-
Principles of ER Co-Translational Translocation Revealed by Proximity-Specific Ribosome ProfilingPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE61012).
Article and author information
Author details
Funding
Howard Hughes Medical Institute (Investigator Program)
- Jonathan S Weissman
Deutsche Forschungsgemeinschaft (Gottfried Wilhelm Leibniz Prize MA 1764/2-1)
- Georg HH Borner
European Research Council (ERC2012-SyG_318987-ToPAG)
- Daniel N Itzhak
Howard Hughes Medical Institute (Faculty Scholar Grant)
- Adam Frost
National Institutes of Health (AG041826)
- Jonathan S Weissman
National Institutes of Health (1DP2GM110772-01)
- Adam Frost
National Institutes of Health (8P41GM103481)
- Alma L Burlingame
National Institutes of Health (1S10OD16229)
- Alma L Burlingame
National Institutes of Health (GM075061)
- Jeffrey Brodsky
Helen Hay Whitney Foundation (Postdoctoral Fellowship)
- Matthew J Shurtleff
Jane Coffin Childs Memorial Fund for Medical Research (Postdoctoral Fellowship)
- Nicole T Schirle Oakdale
Sandler Foundation (Program for Breakthrough Biomedical Research)
- Adam Frost
American Asthma Foundation
- Adam Frost
Louis-Jeantet Foundation
- Daniel N Itzhak
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Alma L Burlingame
Max Planck Society for the Advancement of Science
- Daniel N Itzhak
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2018, Shurtleff et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 14,085
- views
-
- 1,788
- downloads
-
- 201
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.
-
- Cell Biology
- Developmental Biology
A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.